Business · 29/08/2022Updated: 10/17/2026 · 1 min read
FDA Issues Emergency Use Authorization for COVID-19 Biological Product
Summary
The US Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) to Novavax, Inc. for a biological product to combat COVID-19, following a public health emergency declaration by the Secretary of Health and Human Services in March 2020.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →